Background: Breast cancer affects millions of people globally each year, making it a major health concern. The
management of breast cancer has undergone a significant transformation with the introduction of neoadjuvant
chemotherapy (NACT).
Aim and objectives: Neoadjuvant chemotherapy and upfront surgery for breast cancer were compared in terms
of clinicopathological characteristics, surgical techniques, and outcome metrics with the goal of comparing the
outcomes in term of local recurrence rates and metastasis in 2 groups.
Subjects and methods: This is a comparative research, which included (40) women who had been diagnosed
with breast cancer and were split into two groups: In group A: 20 patients underwent upfront surgery, Group B: 20
patients recieved neo adjuvant chemotherapy over a year.
Result: The two study groups differed statistically significantly in terms of local recurrence and metastatic work up.
Conclusion: Neoadjuvant chemotherapy significantly increases the risk of metastasis compared to upfront surgery
while having a marginally positive effect on pathological complete response (PCR) in patients with breast cancer. We
discovered that upfront surgery is preferable in the treatment of early breast cancer, but neoadjuvant chemotherapy
is preferable in the treatment of late breast cancer.